Thread by @TurajlicLab

1st paper📰 Infection Cohort 👉We analysed neutralising and T cell responses in 118 patients with cancer, where SARS-CoV-2 infection was defined by positive PCR or antibody test. COVID-19 severity ranged from asymptomatic to severe (1/6) nature.com/articles/s4301…

Most patient with solid cancer had neutralising antibodies while blood cancer patients had reduced or absent neutralising responses (2/6)

Patients who were infected with either the original strain or the Alpha variant had neutralising responses that were reduced against the Beta and Delta variants (3/6)

Neutralising responses were durable for up to 11 months after infection, even though we observed a decline in S1-reactive antibodies in a proportion of patients (4/6)

SARS-CoV-2-specific CD4+ and CD8+ T cell responses were observed in most patients with solid cancer. Patients with blood cancer had lower levels of CD4+ T cells and CD8+ T cells (5/6)

We found evidence of compensation in patients with blood cancer. Patients treated with anti-CD20 had no neutralising responses, but all had T cell responses, which may have aided clinical recovery of these patients (6/6)